Pretax income is the income that a company earns before paying income taxes. Allogene Therapeutics's pretax income for the
three
months ended in Dec. 2024 was $-59.50 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-257.15 Mil.
Allogene Therapeutics's pretax margin was %.
During the past 8 years, Allogene Therapeutics's highest Pretax Margin was -159.57%. The lowest was -1168850.00%. And the median was -281351.79%.
Allogene Therapeutics Pre-Tax Income Historical Data
The historical data trend for Allogene Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Allogene Therapeutics's Pre-Tax Income
For the Biotechnology subindustry, Allogene Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allogene Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Allogene Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Allogene Therapeutics's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-257.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allogene Therapeutics (NAS:ALLO) Pre-Tax Income Explanation
Allogene Therapeutics's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as
During the past 8 years, Allogene Therapeutics's highest Pretax Margin was -159.57%. The lowest was -1168850.00%. And the median was -281351.79%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allogene Therapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Allogene Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALLO has been successfully added to your 